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Treatment of 2-(2-((3aR,4S,6S,6aS)-6-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-2,2-dimethyltetrahydrofuro 
[3,4-d][1,3]dioxol-4-yl)-4-oxo-3-phenylthiazolidin-5-yl)acetic acid o-phenyl diamine in conventional and microwave 
irradiation gives 5-((1H-benzo[d]imidazol-2-yl)methyl)-2-((3aR,4S,6S,6aS)-6-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-
yl)methoxy)-2,2-dimethyl tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-3-phenylthiazolidin-4-one. Characterization of new 
compounds has been done by means of IR, NMR, MS and elemental analysis. 
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antibacterial activity 
1,2,3-Triazoles are one of the most important classes 
of heterocyclic organic compounds, which are 
reported to present in a plethora of biological 
activities for diverse therapeutic areas
1
. The 1,2,3-
triazole motif is associated with diverse 
pharmacological activities such as antibacterial, 
antifungal, hypoglycemic, antihypertensive and 
analgesic properties. Polysubstituted five-membered 
aza heterocyclic’s rank the most potent glycosidase 
inhibitors
2
. Further, this nucleus in combination with 
or in linking with various other classes of compounds 
such as amino acids, steroids, aromatic compounds, 




modified carbohydrates have became easily available 
after the discovery of the Cu(I) catalyzed azide-
alkynes 1,3-dipolar cycloaddition reaction
4
 and 
quickly became a prominent class of non-natural 
sugars. The chemistry and biology of triazole 
modified sugars is dominated by Triazole glycosides
5
. 
Therefore, the synthesis and investigation of 
biological activity of 1,2,3-triazole glycosides is an 
important objective, which also received the 
considerable attention by the medicinal chemists.  
Thiazoles are familiar group of heterocyclic 
compounds possessing a wide variety of biological 
activities and their utility as medicine is very much 
estabilished
6
. Thiazole nucleus is also integral part of 
all the available pencillins which have revolutionized 
the therapy of bacterial diseases
7
. Furthur the chemistry 
of thiazolidenone ring system is one considerab interest 
as it core structure in various synthetic pharmaceuticals 
displaying a broad spectrum biological activities
8
. The 
thiazolidenone nucleus also appears frequently in the 
structure of various natural products notably thiamine, 
compounds possessing cardiac and glycemic benefits 
such as troglitazone
9
 and many metabolic products of 
fungi and primitive marine animals, including 2- 
(aminoalyl) – thiazole – 4- carboxylic acids
10
. 
Numerous thiazolidenone derivatives have shown 






























, antiplatelet activating 
factor
23
, non- peptide thrombin receptor antagonist
24
, 
tumor necrosis factor- α antagonist
25
 and nematicidal 
activities. Natural biological substances such as purine 
bases and vitamin B
12
 include Benzimidazole moiety in 
their structure. Several Benzimidazole derivatives are 

















Microwave irradiation is an alternative heating 
technique based on the transformation of 
electromagnetic energy into heat. Often this method 
increases the rate of chemical reactions
37
 and results in 
higher yields. Microwave energy couples directly with 
polar molecules or ions and leads to a rapid rise in the 
temperature of reaction medium
38,39
. Reactions that 
require hours or even days using conventional heating 
can usually be completed in minutes or seconds using 




MWs. Several reactions have been performed under 
MW – assisted conditions with significant rate 
enhancements, improved yield, and selectivity
39
. 
Following the successful introduction of 
antimicrobial agents microwave assisted synthesis, 
inspired by the biological profile of triazoles, 
thiazolidinones, benzimidazoles and in the continuation 
of our work on biological active molecules
40-54
 we have 
developed a series of novel hybrid heterocyclics 
(Scheme I, Table I) and investigated the application of 
microwave irradiation for the synthesis of our hybrid 
molecules and evaluated their antbacterial activity. 
 
Antibacterial activity 
The compounds 2a-n were screened for their 
antibacterial activity using the tube-dilution method
55
 
by measuring the minimum inhibitory concentration 
(MIC) in g/mL, against four representative 
organisms viz., Bacillus subtilis. Staphylococcus 
aursus, Escherichia coli and Staphylococcus 
pyogenes. Standard antibacterial agents, such as 
Streptomycin and Neomycin, were also screened 
under identical conditions for comparison. The 
minimum inhibitory concentrations are given in 
Table II. It has been observed that the test compounds 
exhibited an interesting biological activity however, 
with a degree of variation. 
Compounds 2b, 2f, 2i, 2m were highly active against 
B. subtilis, S. aureus and S. pyogenes, the compound 2f 
was highly active against B. subtilis, S. aureus, E. coli 
and the compound 2b was highly active against  





Table I — Synthesis of compounds 2a-n 
Compd R R1 Mol. formula ReactionTime (min) Yield (%) 
9a C6H5 H C33H31ClN6O5S 10 85 
9b C6H5 Cl C30H30Cl2N6O5S 3 76 
9c 4-Cl-C6H4 H C33H30Cl2N6O5S 4 88 
9d 4-Cl-C6H4 Cl C33H29Cl3N6O5S 3 81 
9e 4-NO2-C6H4 H C33H30ClN7O7S 5 85 
9f 4-NO2-C6H4 Cl C33H29Cl2N7O7S 4 90 
9g 2-CH3-C6H4 H C34H33ClN6O5S 8 87 
9h 2-CH3-C6H4 Cl C34H32Cl2N6O5S 12 85 
9i 4-CH3-C6H4 H C34H33ClN6O5S 8 91 
9j 4-CH3-C6H4 Cl C34H32Cl2N6O5S 6 92 
9k 3-OH H C33H31ClN6O6S 7 88 
9l 3-OH Cl C33H30Cl2N6O6S 5 89 
9m 4-OH H C33H31ClN6O6S 8 85 
9n 4-OH Cl C33H30Cl2N6O6S 7 88 




2d did not exhibit any activity against E. coli even at  
100 g/mL concentration (Table II). 
 
Results and Discussion 
Compounds 1a-g on condensation with o- 
phenylenediamine under microwave irradiation in 
presence of HCl yielded compounds 2a-n. The 
reaction is completed in only 5-10 min and the 
compounds, isolated by conventional work - up, are 
obtained in satisfactory yields, often higher than those 
achieved by traditional methods. The structures of 
synthesized compounds have been confirmed by IR, 
NMR, MS and elemental analysis. 
 
Experimental Section 
Commercial grade reagents were used as received. 
Solvents except analytical reagent grade were dried and 
purified according to literature when necessary. Reaction 
progress and purity of the compounds were checked by 
thin-layer chromatography (TLC) on pre-coated silica 
gel F254 plates from Merck and compounds visualized 
either by exposure to UV light or dipping in 1% aqueous 
potassium permanganate solution. Silica gel 
chromatographic columns (60–120 mesh) were used for 
separations. Optical rotations were measured on an 
Perkin – Elmer 141 polarimeter by using a 2 mL cell 
with a path length of 1 dm with CHCl3 or CDCl3 as 
solvent. Microwave reactions are carried out in mini lab 
microwave catalytic reactor (ZZKD, WBFY-201). All 
melting points are uncorrected and measured using 
Fisher–Johns apparatus. IR spectra were recorded as 




C NMR spectra were recorded on a Varian 
Gemini spectrometer (300 MHz for 
1
H and 75 MHz 
for
13
C). Chemical shifts are reported as δ (ppm) against 
TMS as internal reference and coupling constants (J) are 
reported in Hz. Mass spectra were recorded on a VG 
micro mass 7070H spectrometer. Elemental analyses 
(CHN) were determined by a Perkin–Elmer 240 CHN 






A mixture of 1 (0.01mol) and substituted  
o-phenylenediamine (2mmol) catalytic amount of HCl 
were ground thoroughly and transferred to a 50 mL 
flask. After adding a few drops of DMF, the mixture 
was irradiated in a microwave oven at 180 W. 
The progress of reaction was monitored by TLC, with 
a mixture of ethanol and water (9:1) as the eluent. On 
completion, the reaction mixture was cooled, ice cold 
distilled H2O was added, and stirred for a while 
wherein a precipitate was observed. The precipitate 
was collected by filtration, washed with water, dried, 






2a: m.p.221-223°C; IR (KBr): 3414, 3223, 2981, 





H-NMR (500 MHz,DMSO-d6): δ 9.32 (s, 1H, -
NH), 8.06 (s, 1H, Ar-H), 7.52 (d, J = 9.2Hz, 4H,  
Ar-H), 7.44 (d, J = 8.9 Hz, 2H,Ar-H), 7.21(d, 2H,  
Ar-H), 6.73- 7.35 (m, 5H,Ar –H),) 6.15 (s,1H, CHS), 
5.73 (d, J = 4.2 Hz,1H, CH), 4.69 (t, J = 3.9 Hz,1H, 
CH),4.65 (t, 1H,CH), 4.52(s, 2H, OCH2), 3.92 – 3.89 
(m, 1H,CH), 3.31 (dd, J = 9.1,4.2 Hz, 1H, CH), 2.38 
(d, 2H,CH2), 1.53 (s, 3H,CH3), 1.30 (m, 3H,CH3); 
13
C 
NMR (75 MHz, DMSO-d6):  151.4,143.8, 141.2, 
134.2, 128.2, 126.8, 122.1,118.8, 104.2, 80.4, 77.9, 
73.8, 66.1, 53.0, 37.2, 33.9, 25.9; MS: m/z (M
+
+H) 
545. Anal. Calcd for C33H31ClN6O5S: C, 60.13; H, 






phenylthiazolidin-4-one, 2b: m.p.227-229°C; 
IR(KBr): 3410, 3213, 2977, 2960, 2942, 2820, 1614, 
Table II — Antibacterial activity of 2a-m 
Compd 
Minimum inhibition concentration (MIC, g/mL) 
B. subtilis S. aureus E. coli S. pyogenus 
2a 50 25 50 50 
2b 12.5 12.5 25 12.5 
2c 25 25 12.5 12.5 
2d 25 50 25 25 
2e 100 50 50 50 
2f 12.5 12.5 12.5 25 
2g 50 50 100 25 
2h 50 50 - 25 
2i 12.5 25 12.5 12.5 
2j 25 25 25 12.5 
2k 50 100 - 50 
2l 50 50 50 50 
2m 12.5 12.5 25 12.5 
2n 50 25 50 50 
Streptomycin 10 10 10 10 
Neomycin 30 30 30 30 









MHz, DMSO-d6): δ 9.27 (s, 1H, -NH), 8.20 (s, 1H, 
Ar-H), 8.04(s, 1H, Ar-H), 7.51 (d, J = 9.2Hz, 2H, Ar-
H), 7.44 (d, J = 8.9 Hz, 2H,Ar-H), 7.21(d, 2H, Ar-H), 
6.73- 7.35 (m, 5H,Ar –H),) 6.15 (s,1H, CHS),5.73 (d, 
J = 4.2 Hz,1H, CH), 4.69 (t, J = 3.9 Hz,1H, CH),4.65 
(t, 1H,CH), 4.52(s, 2H, OCH2), 3.92 – 3.89 (m, 
1H,CH), 3.31 (dd, J = 9.1,4.2 Hz, 1H, CH), 2.38 (d, 
2H,CH2), 1.53 (s, 3H,CH3), 1.30 (m, 3H,CH3); 
13
C 
NMR (75 MHz, DMSO-d6):  151.4,143.8, 141.2, 
134.2, 128.2, 126.8, 122.1,118.8, 104.2, 80.4, 77.9, 
73.8, 66.1, 53.0, 37.2, 33.9, 25.9; MS: m/z (M
+
+H) 
694. Anal. Calcd for C30H30Cl2N6O5S: C, 57.14; H, 






-yl)thiazolidin-4-one, 2c: m.p.248-250°C; IR(KBr): 
3411, 3220, 2981, 2970, 2944, 2830, 1610, 1542, 




H-NMR (500 MHz, 
DMSO-d6): δ 9.17 (s, 1H, -NH), 8.05 (s, 1H, Ar-H), 
7.50 (d, J = 9.2Hz, 4H, Ar-H), 7.42 (d, J = 8.9 Hz, 
2H,Ar-H), 7.20(d, 2H, Ar-H), 7.10- 6.95 (m, 4H, 
Ar –H), 6.13 (s,1H, CHS),5.71 (d, J = 4.2 Hz,1H, 
CH), 4.66 (t, J = 3.9 Hz,1H, CH),4.60 (t, 1H,CH), 
4.50(s, 2H, OCH2), 3.92 – 3.89 (m, 1H,CH), 3.31 (dd,  
J = 9.1,4.2 Hz, 1H, CH), 2.38 (d, 2H,CH2), 1.53  
(s, 3H,CH3), 1.30 (m, 3H,CH3); 
13
C NMR (75 MHz, 
DMSO-d6):  151.1,143.8, 141.2, 138.9, 134.2, 128.2, 
126.8, 122.1,118.8, 104.2, 80.4, 77.9, 73.8, 66.1, 53.0, 
37.2, 33.9, 25.9; MS: m/z (M
+
+H) 693. Anal. Calcd 
for C33H30Cl2N6O5S: C, 57.13; H, 4.36; N, 12.12. 






yl)thiazolidin-4-one, 2d: m.p.232-234°C; IR(KBr): 
3397, 3211, 2972, 2950, 2932, 2810, 1612, 1532, 




H-NMR (500 MHz, 
DMSO-d6): δ 9.27 (s, 1H, -NH), 8.26 (s, 1H, Ar-H), 
8.04(s, 1H, Ar-H), 7.51 (d, J = 9.2Hz, 4H, Ar-H), 7.44 
(d, J = 8.9 Hz, 4H,Ar-H), 7.21(d, 1H,  
Ar-H),7.11(d, 1H, Ar-H), 6.15 (s,1H, CHS),5.73  
(d, J = 4.2 Hz,1H, CH), 4.69 (t, J = 3.9 Hz,1H, 
CH),4.65 (t, 1H,CH), 4.52(s, 2H, OCH2), 3.92 – 3.89 
(m, 1H,CH), 3.31 (dd, J = 9.1,4.2 Hz, 1H, CH), 2.38 
(d, 2H,CH2), 1.53 (s, 3H,CH3), 1.30 (m, 3H,CH3); 
13
C 
NMR (75 MHz, DMSO-d6):  151.1,143.5, 141.0, 
134.1, 128.4, 126.2, 122.0,116.8, 102.2, 80.1, 77.6, 
73.2, 66.0, 53.0, 37.6, 33.1; MS: m/z (M
+
+Na) 749. 
Anal. Calcd for C33H29Cl3N6O5S: C, 54.14; H, 4.01;  






thiazolidin-4-one, 2e: m.p.256-258°C; IR(KBr): 
3395, 3330, 3220, 2971, 2964, 2819, 1604, 1539, 





(500 MHz, DMSO-d6): δ 9.17 (s, 1H, -NH), 8.21  
(d, J= 8.4 Hz, 2H), 8.01 (s, 1H, Ar-H), 7.49  
(d, J = 9.1Hz, 2H, Ar-H), 7.41 (d, J = 8.5 Hz, 2H, 
Ar-H), 7.30- 7.34(m, 4H, Ar-H), 6.79 (d, J = 9.6 Hz, 
2H,Ar-H), 6.14 (s,1H, CHS), 5.69 (d, J = 4.2 Hz,1H, 
CH), 4.65 (t, 1H,CH), 4.53 (t, J = 3.9 Hz,1H, CH), 
4.52 (s, 2H, OCH2), 3.90 – 3.86 (m, 1H,CH), 3.19 
(dd, J = 9.1,4.2 Hz, 1H, CH), 2.30 (d, 2H,CH2), 1.49 
(s, 3H,CH3), 1.25 (m, 3H,CH3) 
13
C NMR (75 MHz, 
DMSO-d6):  190.2, 173.2, 143.6, 141.9, 134.5, 
128.2, 126.5, 122.2,118.2, 104.3, 80.4, 77.2, 73.1, 
66.2, 52.1, 36.4, 33.1, 25.4; MS: m/z (M
+
+H) 704 
Anal. Calcd for C33H30ClN7O7S: C, 56.70; H, 4.29; N, 






(4-nitrophenyl)thiazolidin-4-one, 2f: m.p.247-248 °C; 
IR(KBr): 3392, 3333, 3221, 2961, 2950, 2815, 1601, 
1529, 1510, 1406, 1378, 1209, 861, 722 cm−1; 
1
H-NMR 
(500 MHz, DMSO-d6): δ 9.14(s, 1H, -NH), 8.36 (s, 1H, 
Ar-H), 8.19 (d, J= 8.4 Hz, 2H), 8.01  
(s, 1H, Ar-H), 7.49 (d, J = 9.1Hz, 2H, Ar-H), 7.41 (d, J = 
8.5 Hz, 2H,Ar-H), 7.34(d, J= 9.3Hz, 2H, Ar-H), 6.79 (d, 
J = 9.6 Hz, 2H,Ar-H), 6.14 (s,1H, CHS), 5.69 (d, J = 4.2 
Hz,1H, CH), 4.65 (t, 1H,CH), 4.53 (t, J = 3.9 Hz,1H, 
CH), 4.52(s, 2H, OCH2), 3.90– 3.86 (m, 1H,CH), 3.19 
(dd, J = 9.1,4.2 Hz, 1H, C3H), 2.30 (d, 2H,CH2),  
1.49 (s, 3H,CH3), 1.25 (m, 3H,CH3) 
13
C NMR (75 MHz, 
DMSO-d6):  190.2, 173.2, 143.6, 141.9, 134.5, 128.2, 
126.5, 122.2,118.2, 104.3, 80.4, 77.2, 73.1, 66.2, 52.1, 
36.4, 33.1; MS: m/z (M
+
+H) 739 Anal. Calcd for 
C33H29Cl2N7O7S: C, 53.60; H, 3.96; N, 13.27.Found: C, 










2g: m.p.247-249°C; IR(KBr): 3331, 3219, 2968, 




H-NMR (300 MHz, DMSO-d6): δ 9.19(s, 1H, -NH), 
8.06 (s, 1H, Ar-H), 7.50 (d, J = 9.1Hz, 2H, Ar-H), 
7.42(d, 2H, Ar-H), 7.38 (d, J = 8.5 Hz, 2H,Ar-H), 
7.34(d, 2H, Ar-H), 7.29- 7.32(m, 4H, Ar-H), 6.14 
(s,1H, CHS),5.65 (d, J = 4.2 Hz,1H, CH), 4.60 (t, 
1H,CH), 4.53 (t, J = 3.9 Hz,1H, CH), 4.54 (s, 2H, 
OCH2), 3.92 – 3.86 (m, 1H,CH), 3.22 (dd, J = 9.1,4.2 
Hz, 1H, C3H), 2.34 (d, 2H,CH2),2.21 (s, 3H,CH3), 
1.51 (s, 3H,CH3), 1.29 (m, 3H,CH3) 
13
C NMR (75 
MHz, DMSO-d6):  191.4, 173.4, 144.6, 142.9, 133.9, 
125.4, 122.2,119.2, 105.6, 80.6, 77.4, 73.4, 66.5, 53.1, 
36.3, 33.2; MS: m/z (M
+
+H) 674. Anal. Calcd for 
C34H33ClN6O5S: C, 60.66; H, 4.94; N, 12.48. Found: 






tolylthiazolidin-4-one, 2h: m.p.257-258°C;IR(KBr): 





H-NMR (500 MHz, DMSO-d6):  
δ 9.17(s, 1H, -NH), 8.29 (s, 1H, Ar-H), 8.06 (s, 1H, 
Ar-H), 7.50 (d, J = 9.1Hz, 2H, Ar-H), 7.42(d,  
J = 8.1Hz, 2H,Ar-H), 7.38 (d, J = 8.5 Hz, 2H,Ar-H), 
7.34(d, 2H, Ar-H), 7.29 (d,J = 9.2Hz, 1H, Ar-H), 
7.14 (d, J = 8.6Hz, 1H, Ar-H), 6.14 (s,1H, CHS),5.65 
(d, J = 4.2 Hz,1H, CH), 4.60 (t, 1H,CH), 4.53  
(t, J = 3.9 Hz,1H, CH), 4.54 (s, 2H, OCH2), 3.92 – 
3.86 (m, 1H,CH), 3.22 (dd, J = 9.1,4.2 Hz, 1H, CH), 
2.34 (d, 2H,CH2),2.21 (s, 3H,CH3), 1.51 (s, 3H,CH3), 
1.29 (m, 3H,CH3) 
13
C NMR (75 MHz, DMSO-d6):  
 191.4, 173.4, 144.6, 142.9, 133.9, 125.4, 
122.2,119.2, 105.6, 80.6, 77.4, 73.4, 66.5, 53.1, 36.3, 
33.2; MS: m/z (M
+
+H) 708. Anal. Calcd for 
C34H32Cl2N6O5S: C, 57.71; H, 4.56; N, 11.88. Found: 






2i: m.p.207-209°C IR(KBr): 3445, 3249, 2971, 2830, 




H-NMR (300 MHz, DMSO-d6): δ 9.12(s, 1H, -NH), 
8.20 (d, J= 8.4 Hz, 2H, Ar-H), 8.04 (s, 1H, Ar-H),7.59 
(d, J = 9.4Hz, 2H, Ar-H) 7.44 (d, J = 9.1Hz, 2H, Ar-
H), 7.32(d, J= 8.9Hz, 2H, Ar-H), 7.21 (d, J= 8.3Hz, 
2H, Ar-H), 7.12 (d, J = 8.3 Hz, 2H, Ar-H), 6.14 (s,1H, 
CHS),5.65 (d, J = 4.2 Hz,1H, CH), 4.60 (t, 1H,CH), 
4.53 (t, J = 3.9 Hz,1H, CH), 4.54 (s, 2H, OCH2), 3.92 
– 3.86 (m, 1H,CH), 3.22 (dd, J = 9.1,4.2 Hz, 1H, CH), 
2.34 (d, 2H,CH2),2.21 (s, 3H,CH3), 1.51 (s, 3H,CH3), 
1.29 (m, 3H,CH3) 
13
C NMR (75 MHz, DMSO-d6):  
 192.4, 175.4, 142.6, 139.9, 136.7,132.9, 124.4, 
121.2,117.2, 104.6, 82.6, 78.4, 73.1, 64.5, 52.1, 35.3, 
31.2, 25.2,21.4,16.2; MS: m/z (M
+
+H) 673. Anal. 
Calcd for C34H33ClN6O5S: C, 60.66; H, 4.94; N, 5.27. 






tolylthiazolidin-4-one, 2j: m.p.217-219°C. IR(KBr): 





H-NMR (300 MHz, DMSO-d6): δ 
9.12(s, 1H, -NH), 8.22 (d, J= 8.4 Hz, 2H, Ar-H), 8.02 (s, 
1H, Ar-H),7.56 (d, J = 9.4Hz, 2H, Ar-H) 7.42 (d, J = 
9.1Hz, 2H, Ar-H), 7.31(d, J= 8.9Hz, 2H, Ar-H), 7.20 (d, 
J= 8.3Hz, 1H, Ar-H), 7.12 (d, J = 8.3 Hz, 2H, Ar-H), 
6.15 (s,1H, CHS),5.63 (d, J = 4.2 Hz,1H, CH), 4.61 (t, 
1H,CH), 4.53 (t, J = 3.9 Hz,1H, CH), 4.51 (s, 2H, 
OCH2), 3.92 – 3.89 (m, 1H,CH), 3.23 (dd, J = 9.1,4.2 
Hz, 1H, CH), 2.35 (d, 2H,CH2),2.20 (s, 3H,CH3), 1.50 
(s, 3H,CH3), 1.25 (m, 3H,CH3) 
13
C NMR (75 MHz, 
DMSO-d6):  192.4, 171.4, 142.6, 140.9, 131.9, 
125.4,123.8, 121.2,118.2, 102.6, 81.6, 76.4, 72.4, 61.5, 
52.1, 33.3, 25.2,23.2,16.2; MS: m/z (M
+
+H) 707. Anal. 
Calcd for C34H32Cl2N6O5S: C, 57.71; H, 4.56; N, 4.88. 






thiazolidin-4-one, 2k: m.p.237-239°C; IR (KBr): 





H-NMR (300 MHz, DMSO-d6):  
δ 9.09 (s,1H,NH), 8.21 (d, J = 8.7Hz, 2H, Ar-H), 8.03 
(s,1H,Ar-H), 7.52 (d, J = 9.2Hz, 2H, Ar-H), 7.14 - 7.10 
(m, 4H,Ar-H), 6.12 (s,1H, CHS), 5.74 (d, J = 3.6 
Hz,1H, CH), 5.40 (s, 1H, OH), 4.96 (d, J = 5.2 Hz,1H, 
CH) 4.49 (t, J = 3.9 Hz,1H, CH), 4.50 (s, 2H, OCH2), 
3.93 – 3.90 (m, 1H,CH), 3.21 (dd, J = 9.1,4.2 Hz, 1H, 
CH), 2.31 (d, 2H,CH2), 1.51 (s, 3H,CH3), 1.35 (m, 
3H,CH3); 
13
C NMR (75 MHz, DMSO-d6):  173.6, 
158.1, 142.2, 140.2, 133.6, 131.4, 130.1, 125.6, 121.2, 
120.1, 116.4, 114.1, 111.8, 105.6,106.2, 80.8, 76.6, 




73.8, 63.9, 52.9, 40.1, 36.9,32.3, 28.1; MS: m/z 
(M
+
+H) 675. Anal. Calcd for C33H31ClN6O6S: C, 








249°C; IR (KBr) 3525, 3426, 3216, 2975, 2832, 





(300 MHz, DMSO-d6): δ 9.09 (s,1H,NH), 8.21 (d, J = 
8.7Hz, 2H, Ar-H), 8.03 (s,1H,Ar-H), 7.52 (d, J = 8.2 
Hz, 1H, Ar-H), 7.14 - 7.10 (m, 4H,Ar-H), 6.12 (s,1H, 
CHS), 5.74 (d, J = 3.6 Hz,1H, CH), 5.40 (s, 1H, OH), 
4.96 (d, J = 5.2 Hz,1H, CH) 4.49 (t, J = 3.9 Hz,1H, 
CH), 4.50 (s, 2H, OCH2), 3.93 – 3.90 (m, 1H,CH), 
3.21 (dd, J = 9.1,4.2 Hz, 1H, CH), 2.31 (d, 2H,CH2), 
1.51 (s, 3H,CH3), 1.35 (m, 3H,CH3); 
13
C NMR (75 
MHz, DMSO-d6):  172.6, 156.1, 141.2, 140.2, 131.6, 
130.4, 129.1, 124.6, 123.2, 121.1, 115.4, 113.1, 112.8, 
104.6,103.2, 82.8, 75.6, 72.8, 62.9, 53.9, 41.1, 
37.9,33.3, 26.1; MS: m/z (M
+
+Na) 729. Anal. Calcd 
for C33H30Cl2N6O6S: C, 55.86; H, 4.26; N, 5.25. 






thiazolidin-4-one, 2m: m.p.266-268°C; IR (KBr) 
3542, 3330, 3216, 2933, 2850, 1718, 1612, 





MHz, DMSO-d6): δ 8.20 (d, J = 8.7Hz, 2H, Ar-H), 
8.02 (s,1H,Ar-H), 7.49 (d, J = 9.2Hz, 2H, Ar-H), 7.14 
– 7.09 (m, 4H,Ar-H), 6.16 (s,1H, CHS), 5.73 (d, J = 
3.6 Hz,1H, CH), 5.41 (s, 1H, OH), 4.94 (d, J = 5.2 
Hz,1H, CH) 4.51 (t, J = 3.9 Hz,1H, CH), 4.54 (s, 2H, 
OCH2), 3.96 – 3.92 (m, 1H,CH), 3.24 (dd, J = 9.1,4.2 
Hz, 1H, CH), 2.33 (d, 2H,CH2), 1.53 (s, 3H,CH3), 
1.38 (m, 3H,CH3); 
13
C NMR (75 MHz, DMSO-d6):  
171.2, 153.1, 142.2, 141.1, 136.6, 134.4, 129.6, 128.4, 
122.2, 120.1, 114.4, 112.2, 111.3, 105.6,103.8, 80.8, 
76.6, 74.8, 65.3, 57.0, 42.5, 36.4, 34.1; MS: m/z 
(M
+
+H) 675. Anal. Calcd for C33H31ClN6O6S: C, 







thiazolidin-4-one, 2n: m.p.246-248°C; IR (KBr) 
3342, 3320, 3206, 2953, 2840, 1716, 1614, 1534,1508, 




H-NMR (300 MHz, DMSO-d6): 
δ 8.19 (d, J = 8.3Hz, 2H, Ar-H), 8.02 (s,1H,Ar-H), 7.38 
(d, J = 9.2Hz, 1H, Ar-H), 7.11 – 7.09 (m, 4H,Ar-H), 
6.12 (s,1H, CHS), 5.70 (d, J = 3.4 Hz,1H, CH),  
5.40 (s, 1H, OH), 4.83 (d, J = 5.1 Hz,1H, CH) 4.50  
(t, J = 3.5 Hz,1H, CH), 4.52 (s, 2H, OCH2), 3.94 – 3.92 
(m, 1H,CH), 3.22 (dd, J = 9.1,4.2 Hz, 1H, CH), 2.30 
(d, 2H,CH2), 1.51 (s, 3H,CH3), 1.34 (m, 3H,CH3); 
13
C 
NMR (75 MHz, DMSO-d6):  154.1, 141.2, 140.1, 
134.6, 132.4, 128.6, 126.4, 121.2, 120.8, 113.4, 112.6, 
110.3, 105.2,103.2, 80.2, 76.2, 74.2, 65.1, 57.0, 42.1, 
36.2, 34.1; MS: m/z (M
+
+H) 709. Anal. Calcd for 
C33H30Cl2N6O6S: C, 55.85; H, 4.24; N, 9.88. Found: C, 
55.72; H, 4.19; N, 9.69. 
 
Conclusion 
In conclusion, a series of a new class of hybrid 
heterocyclics 2a-n have been synthesized, and 
evaluated for their antibacterial activity, most of the 
compounds showed appreciable antibacterial activity. 
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